Sign In

Celine Halioua

Founder & CEO of Cellular Longevity, Inc.

Celine Halioua is the Founder and CEO of Loyal, a biotech company focused on developing drugs to extend the lifespan and improve the health of dogs. Established in 2019, Loyal aims to create the first FDA-approved drug for lifespan extension in any species, starting with canines. Halioua leads a multidisciplinary team that includes neuroscientists, veterinarians, and regulatory experts to achieve this goal.123

Halioua's academic background includes a Bachelor of Science in Neuroscience from the University of Texas at Austin and a D.Phil. (incomplete) from the University of Oxford, where she studied the economics of gene therapy. Before founding Loyal, she served as Chief of Staff at The Longevity Fund, a venture capital firm investing in longevity-related therapies.234

Since its inception, Loyal has raised over $125 million from prominent venture capitalists, including Khosla Ventures and Bain Capital. Halioua's vision extends beyond dogs; she believes that the advancements made through her company could eventually benefit human health as well.23

Highlights

Aug 28 · linkedin

We are hiring a General Manager to lead LOY-002's commercial launch, est. in 2025

You will be directly responsible for launching what we hope will be the first drug FDA approved for extending the healthy lifespan of dogs

Rx dog longevity drugs could be a great new product category:

  • cash-pay
  • consumer marketed
  • no middle-men: just the co, dog owner, & veterinarian
  • high margin (if you optimize COGS as well as we have!)
  • federally enforced exclusivity
  • something people really want!

You should:

  • have 0 -> 1 g2m experience
  • have B2B motion context, ideally w B2B2C
  • be a bonafide dog person who understands the emotional connection btwn dog & human
  • ideally you have worked in or with bio/vet/pharma/Rx/Dx world
  • 1st principles thinking

Learn more here! --> https://lnkd.in/gQsBuSph

Jul 1 · linkedin

Linda Rhodes is joining Loyal's board!

Linda was prev BoD at Zoetis ($79B animal health pharma), founder of AlcheraBio (acq'd by Argenta), + CSO Aratana Therapeutics (3 FDA drugs + acq'd by Elanco).

I'm honored to continue learning from her :)

Related Questions

What inspired Celine Halioua to start Loyal?
How did Celine Halioua raise over $125 million for Loyal?
What are the biggest challenges Celine Halioua has faced as a founder?
How does Loyal's drug work to extend dog lifespan?
What is Celine Halioua's background in neuroscience and biotechnology?
Celine Halioua
Celine Halioua, photo 1
Celine Halioua, photo 2
Add to my network

Experience

Founder & CEO of Cellular Longevity, Inc.
Chief of Staff at The Longevity Fund; Entrepreneur In Residence at The Longevity Fund; Scientific Consultant at Oisín Biotechnologies; Researcher: Neuro-oncology at Sanford Burnham Prebys Medical Disc at Austin

Education

DPhil in Paediatrics (incomplete) at University of Oxford; BSc in Neuroscience at The University of Texas at Austin; Studied Nanotechnology at Uppsala University

Location

San Francisco, California, United States